Bioreliance corp:1108045 [14-055506]
Ended Awarded
- Contract number
- HHSN26100005
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77 Part of Sigma-Aldrich Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,827
Award facts
- Contract value 100% obligated
- $4,827.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a $4.8K firm fixed-price BPA (Blanket Purchase Agreement) call to Bioreliance Corporation on August 12, 2014, with completion targeted for April 30, 2015. The work will be performed at the agency's Bethesda, Maryland location. Bioreliance Corporation, a subsidiary of Sigma-Aldrich Corporation, operates its Life Sciences Services division from Rockville, Maryland and specializes in critical laboratory and testing services for federal health research institutions. The contract carries no set-aside designation, indicating open competition in the scientific testing marketplace.
This award reflects the National Cancer Institute's engagement with Bioreliance for specialized microbiological and pharmaceutical testing capabilities that support the agency's research initiatives. Bioreliance's core competencies include endotoxin testing, sterility testing, Limulus Amebocyte Lysate (LAL) testing, and microbiological examination of pharmaceutical products—services that are fundamental to drug development and investigational processes. As a long-established federal contractor registered in SAM.gov since 2002, Bioreliance has demonstrated sustained capability in delivering testing services across the National Institutes of Health enterprise, supporting critical research in vaccine development and therapeutic product assessment.
Quick answers
Who was awarded contract HHSN26100005?
HHSN26100005 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on August 12, 2014.
How much is contract HHSN26100005 worth?
The government has obligated $4,827 on HHSN26100005.
Is contract HHSN26100005 an order under another contract?
Yes. HHSN26100005 is a BPA call under HHSN263199800048997B, a blanket purchase agreement.
Was contract HHSN26100005 competed?
The extent of competition for HHSN26100005 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award